MRTX - Mirati Therapeutics Inc Stock Price, Fair Value and News

58.70USD Market Closed

Market Summary

USD58.70

Market Closed

MRTX Stock Price

View Fullscreen

MRTX RSI Chart

MRTX Valuation

Market Cap

4.1B

Price/Earnings (Trailing)

-5.67

Price/Sales (Trailing)

107.82

EV/EBITDA

-5.27

Price/Free Cashflow

-6.91

MRTX Price/Sales (Trailing)

MRTX Profitability

EBT Margin

-1929.91%

Return on Equity

-76.69%

Return on Assets

-64.25%

Free Cashflow Yield

-14.47%

MRTX Fundamentals

MRTX Revenue

Revenue (TTM)

38.2M

Rev. Growth (Yr)

201.97%

Rev. Growth (Qtr)

19.8%

MRTX Earnings

Earnings (TTM)

-725.9M

Earnings Growth (Yr)

6.72%

Earnings Growth (Qtr)

8.48%

Breaking Down MRTX Revenue

Last 7 days

-0.8%

Last 30 days

1.8%

Last 90 days

5.6%

Trailing 12 Months

36.5%

How does MRTX drawdown profile look like?

MRTX Financial Health

Current Ratio

7.54

MRTX Investor Care

Shares Dilution (1Y)

21.81%

Diluted EPS (TTM)

-12.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.9M	27.2M	38.2M	0
2022	67.0M	48.8M	30.6M	12.4M
2021	0	0	49.3M	85.2M
2020	5.9M	8.4M	10.9M	13.4M
2019	4.7M	5.3M	6.3M	3.3M
2018	5.6M	8.0M	10.5M	12.9M
2011	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Mirati Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 23, 2024	carter bruce l a	back to issuer	-	-	-17,273	-
Jan 23, 2024	sharp shalini	back to issuer	-	-	-16,222	-
Jan 23, 2024	hickey benjamin	back to issuer	-	-	-117,028	evp, chief commercial officer
Jan 23, 2024	johnson craig a	back to issuer	-	-	-17,273	-
Jan 23, 2024	baum charles m	back to issuer	-	-	-237,871	founder, president, and ceo
Jan 23, 2024	cherrington julie m	back to issuer	-	-	-11,252	-
Jan 23, 2024	sandler alan b.	back to issuer	-	-	-79,865	chief medical officer
Jan 23, 2024	boxer capital, llc	back to issuer	-	-	-3,201,440	-
Jan 23, 2024	martinez maria e	back to issuer	-	-	-17,273	-
Jan 23, 2024	boxer capital, llc	back to issuer	-	-	-3,658,100	-

Which funds bought or sold MRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	sold off	-100	-1,400,070	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-249,218	-	-%
Apr 09, 2024	SYQUANT CAPITAL SAS	sold off	-100	-9,043,000	-	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-70,000	-	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-436	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	1.26	3,808	14,219	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	new	-	22,395,500	22,395,500	0.08%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-6.89	63,492,200	311,768,000	0.01%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	329	7,315,320	8,839,880	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	16.88	9,667	26,438	-%

Are Funds Buying or Selling MRTX?

Are funds buying MRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRTX

No. of Funds

Unveiling Mirati Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	0.71%	5e+05	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	7.0%	4,886,840	SC 13G/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	0.0%	0	SC 13G
Feb 13, 2024	vanguard group inc	7.57%	5,306,693	SC 13G/A
Feb 09, 2024	morgan stanley	8.7%	6,079,302	SC 13G
Feb 09, 2024	morgan stanley	0.0%	0	SC 13G/A
Feb 08, 2024	wellington management group llp	0.00%	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.5%	3,866,202	SC 13G
Jan 25, 2024	boxer capital, llc	0%	0	SC 13D/A

Recent SEC filings of Mirati Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	SC 13G/A	Major Ownership Report
Feb 02, 2024	15-12G	15-12G
Jan 31, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Mirati Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Mirati Therapeutics Inc News

Latest updates

Mirati Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	19.8%	16,400,000	13,690,000	7,167,000	934,000	5,431,000	5,362,000	2,830,500	299,000	71,793,000	1,708,000	11,424,000	7,791,333	4,158,667	526,000	988,000	577,000	1,244,000	3,459,000	-	-	9,467,000
Operating Expenses	-6.2%	188,454,000	200,960,000	200,990,000	212,657,000	191,874,000	182,567,000	184,927,000	197,374,000	151,292,000	108,043,000	100,102,000	84,862,000	89,754,000	75,173,000	58,047,000	48,218,000	44,002,000	33,131,000	28,939,000	28,670,000	24,813,000
S&GA Expenses	-4.6%	72,001,000	75,490,000	73,490,000	70,821,000	60,798,000	54,228,000	53,951,000	43,535,000	35,183,000	25,338,000	20,249,000	19,779,000	18,046,000	12,232,500	10,685,000	9,894,000	9,762,000	6,373,000	5,313,000	4,841,000	5,154,000
R&D Expenses	-7.6%	114,766,000	124,187,000	126,683,000	141,236,000	131,076,000	128,339,000	130,976,000	153,839,000	116,109,000	82,705,000	79,853,000	65,083,000	71,708,000	62,940,500	47,362,000	38,324,000	34,240,000	26,758,000	23,626,000	23,829,000	19,659,000
EBITDA Margin	29.1%	-19.19	-27.06	-39.01	-59.30	-21.06	-13.63	-10.08	-8.00	-6.21	-26.67	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	254,000	254,000	-	-	-	3,299,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-161,904,000	-	-	-202,221,000	-173,307,000	-	-	-199,620,000	-76,755,000	-101,087,000	-87,336,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	29.0%	-19.30	-27.20	-39.18	-59.53	-21.15	-13.69	-10.12	-8.02	-6.23	-26.72	-	-	-	-	-	-	-	-	-	-	-
Net Income	8.5%	-161,904,000	-176,913,000	-184,586,000	-202,475,000	-173,561,000	-176,445,000	-188,386,000	-199,620,000	-80,054,000	-101,087,000	-87,336,000	-82,859,000	-86,655,000	-72,376,000	-54,273,000	-45,695,000	-40,912,000	-28,272,000	-27,568,000	-27,869,000	-14,709,000
Net Income Margin	29.8%	-19.01	-27.09	-39.01	-59.57	-26.98	-15.25	-11.10	-8.07	-8.42	-26.72	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-8.8%	-143,749,000	-132,122,000	-190,451,000	-129,610,000	-139,049,000	-145,153,000	-161,609,000	-140,634,000	-49,041,000	-77,927,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	23.5%	1,130	915	1,034	1,203	1,303	1,280	1,421	1,589	1,253	1,356	1,381	1,476	620	664	713	432	471	501	309	228	248
Current Assets	26.5%	1,036	819	939	1,109	1,226	1,203	1,343	1,508	1,172	1,278	1,304	1,404	595	654	705	424	465	496	306	227	246
Cash Equivalents	99.2%	259	130	242	235	299	266	305	414	243	281	330	886	131	132	205	47.00	92.00	252	75.00	33.00	117
Inventory	133.2%	20.00	9.00	4.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.9%	16.00	17.00	17.00	18.00	18.00	17.00	17.00	16.00	14.00	12.00	9.00	8.00	6.00	3.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00
Liabilities	-1.5%	183	186	171	206	174	168	172	192	169	227	121	115	69.00	59.00	57.00	50.00	36.00	29.00	26.00	27.00	23.00
Current Liabilities	-1.9%	137	140	125	159	127	119	124	144	122	181	77.00	71.00	67.00	58.00	56.00	49.00	35.00	28.00	25.00	26.00	22.00
Shareholder's Equity	29.8%	946	729	863	997	1,129	1,112	1,249	1,397	1,084	1,129	1,259	1,361	551	605	656	382	434	472	284	202	225
Retained Earnings	-5.8%	-2,976	-2,814	-2,637	-2,452	-2,250	-2,076	-1,900	-1,712	-1,512	-1,432	-1,265	-1,130	-1,029	-941	-858	-772	-699	-645	-599	-559	-530
Additional Paid-In Capital	10.7%	3,924	3,545	3,502	3,453	3,386	3,185	3,145	3,100	2,587	2,552	2,516	2,481	1,570	1,535	1,505	1,145	1,124	1,108	874	751	746
Shares Outstanding	20.2%	70.00	58.00	58.00	58.00	56.00	56.00	55.00	55.00	52.00	51.00	51.00	45.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	3,700	-	-	-	7,400	-	-	-	4,433	-	-	-	2,907	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-9.4%	-143,713	-131,400	-190,182	-128,800	-137,809	-143,492	-160,469	-137,985	-47,032	-93,367	-110,416	-76,421	-76,763	-59,343	-59,004	-41,902	-32,874	-38,468	-34,482	-20,795	-20,172
Share Based Compensation	13.1%	44,553	39,399	46,961	61,607	42,992	38,684	42,905	33,878	26,933	27,969	24,722	21,743	21,750	20,787	21,567	16,711	15,106	12,589	11,131	4,262	4,058
Cashflow From Investing	-500.4%	-62,194	15,532	195,151	59,297	13,945	103,006	49,555	-170,838	704	36,761	-455,528	-59,340	64,157	-22,447	-122,227	-6,939	-128,066	-5,927	-35,208	-63,683	28,762
Cashflow From Financing	8609.3%	334,700	3,843	1,727	5,920	157,105	1,392	2,527	479,282	8,232	7,823	9,885	889,889	12,351	9,273	339,201	3,473	1,072	221,882	111,601	462	2,157

MRTX Income Statement

2023-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total revenue	$ 16,400	$ 5,431	$ 37,257	$ 11,502
Revenue
Total revenue	16,400	5,431	37,257	11,502
Operating expenses
Cost of product revenue	1,428	0	3,011	0
Cost of product revenue - intangible asset amortization	259	0	776	0
Research and development	114,766	131,076	365,636	390,391
Selling, general and administrative	72,001	60,798	220,981	168,977
Total operating expenses	188,454	191,874	590,404	559,368
Loss from operations	(172,054)	(186,443)	(553,147)	(547,866)
Other income, net	10,150	13,136	29,744	9,728
Loss before income taxes	(161,904)	(173,307)	(523,403)	(538,138)
Income tax expense	0	254	0	254
Net loss	(161,904)	(173,561)	(523,403)	(538,392)
Unrealized gain (loss) on available-for-sale investments	106	(1)	2,175	(5,712)
Foreign currency translation adjustment	59	(9,485)	(6)	(9,485)
Comprehensive loss	$ (161,739)	$ (183,047)	$ (521,234)	$ (553,589)
Basic net loss per share (USD per share)	$ (2.49)	$ (3.09)	$ (8.66)	$ (9.66)
Diluted net loss per share (USD per share)	$ (2.49)	$ (3.09)	$ (8.66)	$ (9.66)
Weighted average common shares outstanding, basic (shares)	64,993,079	56,219,416	60,419,755	55,747,205
Weighted average common shares outstanding, diluted (shares)	64,993,079	56,219,416	60,419,755	55,747,205
Product Revenue
Total revenue	$ 16,400	$ 0	$ 36,056	$ 0
Revenue
Total revenue	16,400	0	36,056	0
License and Collaboration Revenue
Total revenue	0	5,431	1,201	11,502
Revenue
Total revenue	$ 0	$ 5,431	$ 1,201	$ 11,502

MRTX Balance Sheet

2023-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 258,718	$ 235,260
Short-term investments	717,716	848,577
Accounts receivable, net	14,651	865
Inventory	20,156	3,020
Other current assets	24,839	21,239
Total current assets	1,036,080	1,108,961
Property and equipment, net	16,046	17,540
Intangible asset, net	14,138	14,914
Long-term investment	3,559	3,465
Right-of-use asset	35,066	36,122
Other long-term assets	24,819	21,645
Total assets	1,129,708	1,202,647
Current liabilities
Accounts payable	37,961	38,861
Accrued liabilities	99,418	120,587
Total current liabilities	137,379	159,448
Lease liability	42,203	43,661
Other liabilities	3,661	3,022
Total liabilities	183,243	206,131
Commitments and contingencies (see Note 11)
Shareholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 70,111,309 and 57,854,559 issued and outstanding at September 30, 2023 and December 31, 2022, respectively	70	58
Additional paid-in capital	3,924,237	3,453,066
Accumulated other comprehensive loss	(1,550)	(3,719)
Accumulated deficit	(2,976,292)	(2,452,889)
Total shareholders' equity	946,465	996,516
Total liabilities and shareholders' equity	$ 1,129,708	$ 1,202,647

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

CEO	Dr. Charles M. Baum M.D., Ph.D.
WEBSITE	mirati.com
INDUSTRY	Biotechnology
EMPLOYEES	587

Mirati Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Mirati Therapeutics Inc? What does MRTX stand for in stocks?

MRTX is the stock ticker symbol of Mirati Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirati Therapeutics Inc (MRTX)?

As of Tue Jan 23 2024, market cap of Mirati Therapeutics Inc is 4.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRTX stock?

You can check MRTX's fair value in chart for subscribers.

What is the fair value of MRTX stock?

You can check MRTX's fair value in chart for subscribers. The fair value of Mirati Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mirati Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mirati Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRTX is over valued or under valued. Whether Mirati Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mirati Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRTX.

What is Mirati Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jan 23 2024, MRTX's PE ratio (Price to Earnings) is -5.67 and Price to Sales (PS) ratio is 107.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Mirati Therapeutics Inc's stock?

In the past 10 years, Mirati Therapeutics Inc has provided 0.103 (multiply by 100 for percentage) rate of return.